Novartis AG ADR (NVS)vsViemed Healthcare Inc (VMD)
NVS
Novartis AG ADR
$146.57
-0.87%
HEALTHCARE · Cap: $282.11B
VMD
Viemed Healthcare Inc
$9.97
+0.10%
HEALTHCARE · Cap: $383.68M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 20833% more annual revenue ($56.58B vs $270.28M). NVS leads profitability with a 23.9% profit margin vs 5.5%. NVS trades at a lower P/E of 21.2x. VMD earns a higher WallStSmart Score of 56/100 (C).
NVS
Buy51
out of 100
Grade: C-
VMD
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$146.57
$36.97 premium
Margin of Safety
+57.1%
Fair Value
$19.68
Current Price
$9.97
$9.71 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Revenue surging 25.5% year-over-year
Earnings expanding 29.8% YoY
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Moderate valuation
Smaller company, higher risk/reward
5.5% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : VMD
The strongest argument for VMD centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 25.5% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : VMD
The primary concerns for VMD are P/E Ratio, Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a declining stock while VMD is a growth play — different risk/reward profiles.
VMD carries more volatility with a beta of 1.16 — expect wider price swings.
VMD is growing revenue faster at 25.5% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
VMD scores higher overall (56/100 vs 51/100) and 25.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Viemed Healthcare Inc
HEALTHCARE · MEDICAL DEVICES · USA
Viemed Healthcare, Inc. provides durable home medical equipment and post-acute respiratory health care services to patients in the United States. The company is headquartered in Lafayette, Louisiana.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?